Frontiers in endocrinology · 2025
Association between free triiodothyronine and diabetic retinopathy: insights from a longitudinal cohort study and Mendelian randomization.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feng Xiaotong, Zhao Hongling, Xu Yongsong, Li Xianhua, Cao Haodi, Wang Yingxiang, Zhao Dong, Ke Jing
Аннотация
BACKGROUND: Growing evidence indicates that thyroid function plays a critical pathophysiological role in diabetic microvascular complications. Nevertheless, the specific association between thyroid hormones, particularly free triiodothyronine (fT3), and diabetic retinopathy (DR) remains controversial.
METHODS: After applying the inclusion and exclusion criteria, 3703 patients were included in the baseline analysis. Multivariate logistic regression models were employed to assess the cross-sectional association between baseline fT3 levels and both the prevalence of DR. Subsequently, 1476 patients who underwent follow-up fundus photography were eligible for the retrospective cohort study. This secondary analysis examined the relationship between baseline fT3 quartiles and the risk of DR onset or progression. Additionally, two-sample Mendelian randomization (MR) analysis was performed to analyze the causal effect of circulating fT3 on non-proliferative DR (NPDR) and proliferative DR (PDR).
RESULTS: In the cross-sectional analysis, higher fT3 levels were inversely associated with DR after multivariable adjustment, including NPDR (OR = 0.61, 95% CI: 0.50-0.74) and PDR (OR = 0.24, 95% CI: 0.13-0.44). In the longitudinal cohort, patients with moderate fT3 levels (Q2-Q3) had a lower risk of DR onset or progression versus the lowest quartile (Q1). This protective association remained significant in those with suboptimal glycemic control (HbA1c ≥7%) or longer diabetes duration (≥ 10 years), with risk reductions of 43% (Q2) and 37% (Q3) in the former, and 44% (Q2) and 49% (Q3) in the latter. Notably, among older patients (≥ 55 years), the benefit extended across Q2-Q4. Finally, the MR analysis suggested a potential protective effect of higher fT3 levels on NPDR (MR Egger, OR = 0.131, 95% CI: 0.023-0.755, P = 0.044).
CONCLUSION: In conclusion, our study demonstrated an inverse association between fT3 levels and the risk of both NPDR and PDR. Moderate fT3 levels were associated with a lower risk of DR onset or progression, particularly among patients with suboptimal glycemic control (HbA1c ≥7%) or longer diabetes duration (≥ 10 years). In older patients (≥ 55years), even relatively higher fT3 levels may be protective. MR analysis suggested a potential protective effect of elevated fT3 levels on the risk of NPDR, which was significant only in the MR Egger model.
METHODS: After applying the inclusion and exclusion criteria, 3703 patients were included in the baseline analysis. Multivariate logistic regression models were employed to assess the cross-sectional association between baseline fT3 levels and both the prevalence of DR. Subsequently, 1476 patients who underwent follow-up fundus photography were eligible for the retrospective cohort study. This secondary analysis examined the relationship between baseline fT3 quartiles and the risk of DR onset or progression. Additionally, two-sample Mendelian randomization (MR) analysis was performed to analyze the causal effect of circulating fT3 on non-proliferative DR (NPDR) and proliferative DR (PDR).
RESULTS: In the cross-sectional analysis, higher fT3 levels were inversely associated with DR after multivariable adjustment, including NPDR (OR = 0.61, 95% CI: 0.50-0.74) and PDR (OR = 0.24, 95% CI: 0.13-0.44). In the longitudinal cohort, patients with moderate fT3 levels (Q2-Q3) had a lower risk of DR onset or progression versus the lowest quartile (Q1). This protective association remained significant in those with suboptimal glycemic control (HbA1c ≥7%) or longer diabetes duration (≥ 10 years), with risk reductions of 43% (Q2) and 37% (Q3) in the former, and 44% (Q2) and 49% (Q3) in the latter. Notably, among older patients (≥ 55 years), the benefit extended across Q2-Q4. Finally, the MR analysis suggested a potential protective effect of higher fT3 levels on NPDR (MR Egger, OR = 0.131, 95% CI: 0.023-0.755, P = 0.044).
CONCLUSION: In conclusion, our study demonstrated an inverse association between fT3 levels and the risk of both NPDR and PDR. Moderate fT3 levels were associated with a lower risk of DR onset or progression, particularly among patients with suboptimal glycemic control (HbA1c ≥7%) or longer diabetes duration (≥ 10 years). In older patients (≥ 55years), even relatively higher fT3 levels may be protective. MR analysis suggested a potential protective effect of elevated fT3 levels on the risk of NPDR, which was significant only in the MR Egger model.